RxElite (OTCPK:RXEI) - Stock Price, News & Analysis

RXEI Stock Overview

Engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. More details

RXEI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($12K)

Shares are highly illiquid

RxElite, Inc. Competitors

Lucy Scientific Discovery

OTCPK:LSDI.F

US$8.8k

Hero Technologies

OTCPK:HENC

US$563.0

CBD Life Sciences

OTCPK:CBDL

US$1.4m

Veritas Farms

OTCPK:VFRM

US$81.9k

Price History & Performance

Summary of all time highs, changes and price drops for RxElite
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	9,900.00%
Change since IPO	-99.99%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	RXEI	US Pharmaceuticals	US Market
7D	0%	2.6%	0.5%
1Y	n/a	13.1%	30.7%

Return vs Industry: Insufficient data to determine how RXEI performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how RXEI performed against the US Market.

Price Volatility

Is RXEI's price volatile compared to industry and market?
RXEI volatility
RXEI Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: RXEI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine RXEI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	www.piramalcriticalcare.com

RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. Its products include Sterile Liquid Dose products that consist of generic ophthalmic products in unit and multi-dose presentations, sterile unit dose inhalation respiratory products, and injectable drugs. The company, through its subsidiaries, also manufactures active pharmaceutical ingredients for pharmaceutical companies in the United States, Europe, and Asia.

RxElite, Inc. Fundamentals Summary

How do RxElite's earnings and revenue compare to its market cap?
RXEI fundamental statistics
Market cap	US$11.67k
Earnings (TTM)	-US$29.23m
Revenue (TTM)	US$10.44m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is RXEI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RXEI income statement (TTM)
Revenue	US$10.44m
Cost of Revenue	US$9.24m
Gross Profit	US$1.20m
Other Expenses	US$30.43m
Earnings	-US$29.23m

Last Reported Earnings

Sep 30, 2008

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did RXEI perform over the long term?

See historical performance and comparison